Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Teva
McKesson
Cerilliant
Citi
QuintilesIMS
Healthtrust
US Army

Generated: February 21, 2019

DrugPatentWatch Database Preview

TUXARIN ER Drug Profile

« Back to Dashboard

When do Tuxarin Er patents expire, and when can generic versions of Tuxarin Er launch?

Tuxarin Er is a drug marketed by Mainpointe and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-eight patent family members in eleven countries.

The generic ingredient in TUXARIN ER is chlorpheniramine maleate; codeine phosphate. There are twenty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorpheniramine maleate; codeine phosphate profile page.

Summary for TUXARIN ER
International Patents:58
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 1
Formulation / Manufacturing:see details
DailyMed Link:TUXARIN ER at DailyMed
Drug patent expirations by year for TUXARIN ER
Synonyms for TUXARIN ER
60540-98-9
Chlorpheniramine maleate / codeine phosphate
Chlorpheniramine maleate and codeine phosphate
Chlorpheniramine maleate mixture with codeine phosphate
Codeine Phosphate / Chlorpheniramine Maleate
Codeine Phosphate and Chlorpheniramine Maleate
Zodryl AC

US Patents and Regulatory Information for TUXARIN ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for TUXARIN ER

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Argus Health
McKesson
Cipla
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Fish and Richardson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.